SGLT2 Inhibitor Role for Isolated Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.
Medscape Medical News
source https://www.medscape.com/viewarticle/983521?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/983521?src=rss
Comments
Post a Comment